Drug Safety Update: Volume 3, Issue 8, March 2010

In this issue

Drug safety advice

• Natalizumab (Tysabri): risk of progressive multifocal leukoencephalopathy increases after two years of therapy.
• Fluoxetine: possible small risk of congenital cardiac defects, similar to that with paroxetine.

Stop press

• Sirolimus: different immunoassays for therapeutic drug monitoring—risk of incorrect dose adjustment.

Other information from the MHRA

• Drug Safety Update gains NHS Evidence accreditation.
• MHRA conference for doctors in training.
• Patient Information Leaflet of the month: Human Varicella-Zoster Immunoglobulin vaccine.